Cidara Therapeutics, Inc. (CDTX)
|52 Week Range||0.465-2.1|
|1y Target Est||-|
|DCF Unlevered||CDTX DCF ->|
|DCF Levered||CDTX LDCF ->|
|Debt / Equity||54.21%||Buy|
Upgrades & Downgrades
Latest CDTX news
Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO ...
30 November 2023
Preclinical data on dual CD73/PD-1 targeting DFC to be presented for the first time Preclinical data on dual CD73/PD-1 targeting DFC to be presented for the first time
Cidara Therapeutics: Reduced Risk Due To Janssen's Decision And Progress In The Oncology Pipeline
22 September 2023
Janssen's decision to proceed with CD388 further de-risks Cidara Therapeutics (CDTX) and validates the potential of the Cloudbreak platform. Combined with impressive preclinical data by oncology candi...
Cidara to Present at the 25th Annual H.C. Wainwright Global Investment Conference
6 September 2023
SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunother...
Cidara shares surge 18.5% as J&J unit Janssen takes lead on flu drug
6 September 2023
Shares of Cidara Therapeutics soared 18.5% in early New York trading, buoyed by news that Janssen Pharmaceuticals, a subsidiary of healthcare giant Johnson & Johnson (NYSE:JNJ) Inc, is set to champion...
Want to Get Rich? 3 Game-Changing Penny Stocks to Buy Right Now
28 August 2023
As a rule of thumb, you should stay away from penny stocks. When you see shares priced near a buck (or even below), there's usually a reason for it – and not a good one.
Cidara Therapeutics: Leveraging Antifungals To Move Into Cancer Therapy
10 August 2023
Cidara Therapeutics is a biotech company with an approved antifungal drug, Rezzayo, but its sales are not enough to offset expenses. The company's pipeline includes antifungal and antiviral agents, wi...
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates
3 August 2023
Cidara Therapeutics (CDTX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.19 per share a year ago.
Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Target...
20 June 2023
SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for pat...
Cidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit
13 June 2023
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for pat...